NCT01595997View on ClinicalTrials.gov

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions
Mild-to-moderate Psoriasis Vulgaris
Interventions
DRUG

DLX105

intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10

Trial Locations (2)

48149

Universitätsklinikum Münster (UKM), Münster

Unknown

Universitätsklinikum, Vienna

Sponsors
All Listed Sponsors
lead

Delenex Therapeutics AG

INDUSTRY